Example searches

QGEN QIAGEN NV

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Company profile

Ticker
QGEN
Exchange
NYSE
Website
www.qiagen.com
CEO
Thierry Bernard
Employees
Incorporated
Netherlands
Location
Netherlands
Fiscal year end
Dec 31
Sector
Health Technology > Medical Specialties
Industry (SIC)
Biological Products, (No Diagnostic Substances)
Amgen • Gilead Sciences • Biogen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics • Innate Pharma ...
Former names
QIAGEN NV
SEC CIK
0001015820
Corporate docs

QGEN stock data

(
)

Calendar

2 Mar 20
27 Sep 20
31 Dec 20

News

Institutional ownership Q2 2020

QGEN institutional ownership history Ownership history
61.7% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 273 257 +6.2%
Opened positions 55 47 +17.0%
Closed positions 39 82 -52.4%
Increased positions 75 75 –
Reduced positions 98 99 -1.0%
13F shares
 Current Prev Q Change
Total value 12.57B 15.22B -17.4%
Total shares 140.78M 141.37M -0.4%
Total puts 442.3K 846.33K -47.7%
Total calls 633.7K 855.1K -25.9%
Total put/call ratio 0.7 1.0 -29.5%
Largest owners
 Shares Value Change
Primecap Management 13.13M $562.24M -8.4%
CS Credit Suisse 10.29M $440.49M +77.5%
C Citigroup 10.2M $436.51M +81.8%
Massachusetts Financial Services 9.14M $391.3M -19.2%
Vanguard 7.39M $316.34M -1.5%
Davidson Kempner Capital Management 5.62M $242.14M +355.0%
BLK BlackRock 4.65M $198.92M -4.4%
JPM JPMorgan Chase & Co. 4.21M $180.02M -25.9%
BAC Bank of America 3.92M $168M +39.5%
Victory Capital Management 3.04M $130.26M -15.5%
Largest transactions
 Shares Bought/sold Change
Wellington Management 2.09M -9.96M -82.7%
C Citigroup 10.2M +4.59M +81.8%
CS Credit Suisse 10.29M +4.49M +77.5%
FIL 1.03K -4.41M -100.0%
Davidson Kempner Capital Management 5.62M +4.39M +355.0%
UBS UBS 2.74M -2.44M -47.1%
Caisse De Depot Et Placement Du Quebec 2.42M +2.38M +5516.3%
Massachusetts Financial Services 9.14M -2.17M -19.2%
Davide Leone & Partners Investment 1.71M +1.71M NEW
JPM JPMorgan Chase & Co. 4.21M -1.47M -25.9%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Guided Therapeutics • Ngen • Luminex • Cepheid • Biocept • Third Wave • Exact Sciences • China Medical • Rosetta Genomics • WaferGen Bio-systems
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: agile, alphanumeric, AMG, Amgen, array, Baar, Bernard, bore, catalysation, CDLT, cervix, CGR, channel, clarity, codified, Cohn, compromise, concept, conclusion, Concord, configured, constant, criterion, cycle, Daktari, departure, descriptor, dissimilar, Dubai, dx, Editorial, eruption, Eurozone, Evotec, fell, FGFR, fifty, flat, flu, format, formatted, fruit, gap, GDF, gel, Glovsky, Heilpflanzenwohl, HepatoChem, hindsight, hub, hybridization, Illumina, implicit, impractical, incidence, Inline, Inovio, inquired, inquiring, intraperiod, Janssen, kinase, LabCorp, lessee, lessor, LLP, Mettmann, mid, Mintz, MiSeq, NaN, NCCN, NextSeq, NSE, Oncimmune, OneMed, outbreak, outweighed, PLA, plasma, Po, Popeo, Predefined, prioritize, prioritized, QBS, QIAcuity, Quanta, Quest, reoriented, resigned, resume, ROU, secondary, shift, shifted, shifting, solving, standby, superseded, supposed, Syrian, Taal, Tellacq, Thierry, Tiangen, toolbox, tough, transcription, TVM, underpayment, undiscounted, unwanted, urothelial, volcano, Wellington, XBRL
Removed: acceleration, accomplishment, AdnaTest, AdvaMedDx, advocacy, ALDA, America, AOCI, automate, bacteria, Basel, batch, benchtop, biomedical, bottleneck, box, BRAF, buyout, Centeon, centralization, chairwoman, characterizing, Chicago, circulating, clause, cleanup, closed, closure, commencing, Computerland, connected, connectivity, Connought, constituting, CPI, cycler, decipher, dedicated, deduct, Deferral, delivering, Dept, descriptive, discovered, disseminate, disseminating, dramatic, DRG, eliminating, enrichment, escalating, everyday, exceeded, Exiqon, explore, exponentially, extending, extinguishment, fellow, flagship, frozen, furniture, FY, Gallen, GeneRead, Graduate, Greene, Halpert, handle, hereditary, hereto, hiring, Hombrechtikon, HSE, huge, influencing, ipsogen, isolation, Karobath, Lieberman, LNA, loading, Locked, Manfred, microbial, microbiome, mine, missing, myeloproliferative, negligible, notion, overseen, participated, partnered, Pasteur, pharmacogenomic, portal, postdoctoral, Poulenc, predominance, prenatal, prepayment, pretax, Prof, prostate, provisional, PS, Psychiatry, QFT, QIAact, quantifiable, random, ratio, realignment, reallocation, redemption, Regeneron, relieve, relocation, Removal, renewal, Rent, rental, revolution, Rhone, richest, robustly, rollout, Rorer, rose, rotary, RPR, Sandoz, scalable, seamlessly, securitization, setup, show, showed, slightly, Society, soil, stand, study, tenor, Triangle, Trustee, turning, varying, vast, Vedbaek, versatile, Veteran, Vienna, virtually, visualize, Waltham, wave, web, Workbench
From filing 20-F 2019 FY

Financial reports

View all
20-F
2019 FY
Annual report (foreign)
2 Mar 20
20-F
2018 FY
Annual report (foreign)
6 Mar 19
20-F
2017 FY
Annual report (foreign)
6 Mar 18
20-F
2016 FY
Annual report (foreign)
6 Mar 17
20-F
2015 FY
Annual report (foreign)
29 Feb 16
20-F
2014 FY
Annual report (foreign)
2 Mar 15
20-F
2013 FY
Annual report (foreign)
3 Mar 14
20-F
2012 FY
Annual report (foreign)
4 Mar 13
20-F
2011 FY
Annual report (foreign)
27 Mar 12
20-F
2010 FY
Annual report (foreign)
21 Mar 11

Current reports

View all
6-K
Current report (foreign)
21 Aug 20
6-K
Current report (foreign)
13 Aug 20
6-K
Current report (foreign)
5 Aug 20
6-K
Current report (foreign)
5 Aug 20
6-K
Current report (foreign)
5 Aug 20
6-K
Current report (foreign)
16 Jul 20
6-K
Current report (foreign)
13 Jul 20
6-K
Current report (foreign)
9 Jul 20
6-K
Current report (foreign)
8 May 20
6-K
Current report (foreign)
8 May 20

Registration and prospectus

View all
SC 14D9/A
Tender offer solicitation (amended)
13 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
13 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
11 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
10 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
7 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
6 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
5 Aug 20
SC 14D9/A
Tender offer solicitation (amended)
5 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
5 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
3 Aug 20

Proxies

No filings

Other

View all
SD
Conflict minerals disclosure
30 Mar 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
2 Mar 20
UPLOAD
Letter from SEC
2 Oct 19
CORRESP
Correspondence with SEC
25 Sep 19
UPLOAD
Letter from SEC
16 Sep 19
SD
Conflict minerals disclosure
8 May 19
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
6 Mar 19
SD
Conflict minerals disclosure
17 May 18
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
6 Mar 18
SD
Conflict minerals disclosure
24 Apr 17

Ownership

View all
SC 13D
QIAGEN / DAVIDSON KEMPNER PARTNERS ownership change
3 Aug 20
SC 13G/A
Qiagen NV
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G/A
Beneficial ownership report (amended)
4 Feb 20
SC 13G
Beneficial ownership report
28 Jan 20
SC 13G/A
Beneficial ownership report (amended)
7 Jun 19
SC 13G
Qiagen NV
13 Feb 19
SC 13G/A
Qiagen NV
8 Feb 19
SC 13G/A
Beneficial ownership report (amended)
6 Feb 19
SC 13G/A
Qiagen NV
28 Jan 19